LGALS3 and heart failure: Van der Velde et al. [29] examined 1,196 patients with chronic HF in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) cohorts and showed that rising galectin-3 levels over time significantly predicted hospitalizations and mortality, even after adjustment for renal function.